Company news
PMGC Holdings Inc. news in 2024
PMGC Holdings Inc.'s news releases, calls and decks from 2024, newest first.
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
December 19, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
December 8, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
December 5, 2024
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
December 3, 2024
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
November 21, 2024
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
November 21, 2024
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
November 13, 2024
CORRECTION - Elevai Labs Inc.
November 13, 2024
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
November 3, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
October 21, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
October 20, 2024
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
October 3, 2024
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 2, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
October 1, 2024
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
September 22, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
September 9, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
September 2, 2024
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
August 27, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
August 25, 2024
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
August 18, 2024
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
July 29, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
June 27, 2024
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
June 25, 2024
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 13, 2024
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
May 28, 2024
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
May 21, 2024
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
May 16, 2024
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
May 14, 2024
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 1, 2024
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
April 30, 2024
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
April 30, 2024
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
April 28, 2024
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
March 28, 2024
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
January 23, 2024
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
January 16, 2024
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 15, 2024
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
January 1, 2024
Decks in 2024
- Elevai Labs — Investor Presentation (September 2024)
Investor deck · 28 slides · Sep 4, 2024
- Elevai Labs — Investor Presentation (July 2024)
Investor deck · 66 slides · Jul 16, 2024